Expression of drug pathway proteins is independent of tumour type

Journal of Pathology

Volumn 209, Issue 2, 2006, Pages 213-219

  Zhang, W ^a   Shannon, W D ^a   Duncan, J ^a   Scheffer, G L ^b   Scheper, R J ^b   McLeod, H L ^a  

^a USA   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Immunohistochemistry; Irinotecan; Tissue microarray

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ABC TRANSPORTER C2; ABC TRANSPORTER C3; ABC TRANSPORTER C5; BREAST CANCER RESISTANCE PROTEIN; CARBOXYLESTERASE 2; CELL PROTEIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN TOP1; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER LOCALIZATION; CANCER THERAPY; CANCER TISSUE; CELL TRANSPORT; CLUSTER ANALYSIS; COLON CANCER; CONTROLLED STUDY; DRUG DISPOSITION; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LYMPHOMA; MELANOMA; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; BREAST NEOPLASMS; CAMPTOTHECIN; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOMA; MALE; MELANOMA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 33744456008     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1955     Document Type: Article

References (27)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-615.
2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
3. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 2002;99:4592-4595.
4. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for 'Can't Predict Toxicity'? J Clin Oncol 2002;20:7-8.
5. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004;5:835-843.
6. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990;50:5919-5924.
7. Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989;81:1732-1735.
8. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A 1987;84:5565-5569.
9. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994;17:662-664.
10. Aogi K, Nishiyama M, Kim R, Hirabayashi N, Toge T, Mizutani A, et al. Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. Int J Cancer 1997;72:295-300.
11. Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 1999;288:735-741.
12. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002;8:2605-2611.
13. Zhang W, Xu G, McLeod HL. Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol 2002;10:374-380.
14. Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000;60:5269-5277.
15. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, Schroeijers AB, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 2000;60:2589-2593.
16. McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996;74:508-512.
17. Wu MH, Yan B, Humerickhouse R, Dolan ME. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res 2002;8:2696-2700.
18. Hammock L, Lewis M, Phillips C, Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003;34:1043-1047.
19. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002;15:1374-1380.
20. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 2003;16:403-410.
21. Callagy G, Pharoah P, Chin SF, Sangan T, Daigo Y, Jackson L, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005;205:388-396.
22. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901-15905.
23. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 2002;8:68-74.
24. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-540.
25. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
26. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-1571.
27. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004;96:1585-1592.